/Companies

Bicycle

NASDAQ: BCYC

Cambridge, GB · Founded 2009 · 264 employees on LinkedIn · 11 known investors

Find your way into Bicycle

244 people in our graph share verified history with the Bicycle team — schools, employers, funds. One of them is your warm intro.

Anne Horganunlockedknows MICHAEL SKYNNER · together at Cambridge Biotechnology Ltd (overlapped)
knows the team · via Crescendo Biologics
knows the team · via Cambridge Biotechnology Ltd
knows the team · via Medivir AB
knows the team · via Nodthera
×4knows the team · via Bicycle

Bicycle Therapeutics develops precision-guided therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, designed to penetrate deep into tissues and target intractable solid tumor cancers. Beyond oncology, it collaborates with pharmaceutical partners and academic groups to apply the technology to other therapeutic areas including anti-infective, cardiovascular, ophthalmology, dementia, CNS, neuromuscular and respiratory conditions.

Founders & leadership

Bicycle was founded in 2009 by Gregory Winter.

GWGregory Winter
Gregory WinterFounderInvestor at Cambridge Innovation Capital
KLKEVIN LEE
KEVIN LEEChief Executive Officer
NCNIGEL CROCKETT
NIGEL CROCKETTDistinguished FellowHe holds a PhD in Molecular Biology from Cambridge University and a BSc in Chemistry from the University of Manchester, and brings nearly three decades of commercial experience in pharmaceuticals and biotech, including prior roles as VP Business Development at Astex Therapeutics and Commercial Director at Cantab Pharmaceuticals, as well as founding Tukan Partners, a biotech consultancy, in 2005.
NKNICHOLAS KEEN
NICHOLAS KEENExecutive
SASANTIAGO ARROYO
SANTIAGO ARROYOChief Development Officer (CDO)2023–2025
MH
MICHAEL HANNAYExecutive
MS
MICHAEL SKYNNERChief Scientific OfficerMichael Skynner is an executive officer at Bicycle Therapeutics, which develops bicyclic peptide-based therapeutics for oncology and other disease areas. He brings experience across senior roles in biotechnology and pharmaceuticals, with expertise in oncology and molecular biology.
KLKevin Lee
Kevin LeeChief Executive Officer
KL
Kevin Lee, Ph.D., MBAChief Executive Officer and Director

Board

FJ
FELIX J. BAKERBoard director
RN
RICHARD N. KENDERBoard director
SS
STEPHEN SANDSBoard director

Investors · 11

Longwood Fundlisted by Longwood FundBoston

How we know: Longwood Fund's portfolio page · the S-1 prospectus · the VCSheet dataset · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$555.5M disclosed across 1 round · 2024

▶$555.5MraisedJun 2024 · 19 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • KEVIN LEEExecutive Officer, Director
  • FELIX J. BAKERDirector
  • RICHARD N. KENDERDirector
  • GREGORY WINTERDirector
  • STEPHEN SANDSDirector
  • NIGEL CROCKETTExecutive Officer
  • JOSE-CARLOS GUTIERREZ-RAMOSDirector
  • NICHOLAS KEENExecutive Officer
  • SANTIAGO ARROYOExecutive Officer
  • PIERRE LEGAULTDirector
  • MICHAEL HANNAYExecutive Officer
  • MICHAEL SKYNNERExecutive Officer
  • ALISTAIR MILNESExecutive Officer
  • ALETHIA YOUNGExecutive Officer
  • JANICE BOURQUEDirector
Offering amount
$555.5M
Amount sold
$555.5M
Sales commissions
$10.1M
Placement agents
JEFFERIES LLC
First sale
May 2024
Incorporated
Other, United Kingdom
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events
$248Mvaluation at IPOMay 2019 · $14.00/share · 424B4
filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Founder mafia

2 people who came through Bicycle went on to found or lead other companies.

Companies House · registry record

View on Companies House ↗
Registered name
BICYCLE LIMITED
Company number
06331421
Status
Active
Company type
Private limited company
Incorporated
2 Aug 2007
Registered office
120a Sheen Road, Richmond, Surrey, TW9 1UR
Nature of business (SIC)
47640 — Retail sale of sports goods, fishing gear, camping goods, boats and bicycles
Accounts
last made up to 31 Jul 2026 · next due 30 Apr 2028
Confirmation statement
last made up to 1 Aug 2026 · next due 15 Aug 2027

Current officers · 3

  • James Yeong Hope — secretary, appointed 2 Aug 2015
  • James Yeong Hope — director, appointed 2 Aug 2007
  • James Thomas — director, appointed 5 Feb 2019

Source: Companies House public register · retrieved 27 Sept 2026. Contains public sector information licensed under the Open Government Licence v3.0.

Frequently asked questions

What does Bicycle do?
Bicycle Therapeutics develops precision-guided therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, designed to penetrate deep into tissues and target intractable solid tumor cancers. Beyond oncology, it collaborates with pharmaceutical partners and academic groups to apply the technology to other therapeutic areas including anti-infective, cardiovascular, ophthalmology, dementia, CNS, neuromuscular and respiratory conditions.
Who founded Bicycle?
Bicycle was founded by Gregory Winter in 2009.
Who are Bicycle's investors?
Bicycle's investors include Ahren Innovation Capital, Astellas Venture Management LLC, Cambridge Innovation Capital, Dementia Discovery Fund, Longwood Fund, Ridgeback Capital, SR One Capital Management, SV Health Investors and 3 more.
How much funding has Bicycle raised?
Bicycle has disclosed $555.5M raised across 1 round.
Where is Bicycle headquartered?
Bicycle is headquartered in Cambridge, GB.